Fitness Trends Global Oncology Drugs Market | Page 3

for drug discovery by identifying potential new targets and combination therapies in
immune-oncology.
4. Novartis’s aims to develop approaches for extending the lives of people suffering from
cancer, by adopting the strategy to use science-based innovation for delivering better
patient outcomes in growing areas of healthcare. Novartis operates in two business
segments namely Novartis Oncology and Novartis Pharmaceuticals, which together form
Innovative Medicines Division. The Novartis Oncology segment contributed around 39% of
its net sales, it was valued around US$ 12.8 Bn. Increase in revenue is attributed to the
strong performance for oncology products Tafinlar + Mekinist, a combination therapy for
advanced melanoma, and Jakavi, for blood cancers. Novartis is leading provider of cancer
treatments, following the acquisition of oncology products from GlaxoSmithKline in 2015.
In 2016, the company collaborated with Surface Oncology to bolster the cancer
immunotherapy pipeline that will provide access to four preclinical programs. Also, with
a licensing agreement with Xencor, it plans to co-develop two bispecific antibodies
designed to target acute myeloid leukemia and B-cell malignancies, thereby aiding the
growth of oncology drugs market.
Sanofi operates through two business segments namely pharmaceuticals and vaccines. Sanofi
gains insights through its network of collaborations with biotech companies such as Immunogen
and Evotec, academic cancer centers such as Institut Gustave Roussy, Institut Curie, and the
Dana Farber Cancer Institute, enabling superior use of software, analytics, and new technology,
which helps to increase its productivity, maximize return on R&D investment, and accelerate
the development of new products. Sanofi Oncology has a large number of collaborations and
alliances to support its R&D portfolio. In 2015, Sanofi collaborated with Regeneron focusing on
cancer immunotherapy to generate high value development candidates in the emerging field of
immuno-oncology and to accelerate its development pipeline in the oncology drugs market. In
2016, the company entered into a collaboration with Innate Pharma to develop innovative
bispecific antibody formats engaging natural killer (NK) cells to kill tumor cells. Also, it
collaborated with Warp Drive Bio to develop drugs targeting human oncogenes, thus
accelerating the innovations for oncology drugs.
Report includes chapters which deeply display the following deliverable about industry :
• Global Oncology Drugs Market Research Objective and Assumption
• Global Oncology Drugs Market Purview - Report Description, Executive Summary, and